Published in Pharmacoeconomics on January 01, 2010
A call to action for comprehensive HIV services for men who have sex with men. Lancet (2012) 2.70
HIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996-2011. J Acquir Immune Defic Syndr (2013) 0.96
Costing analysis of national HIV treatment and care program in Vietnam. J Acquir Immune Defic Syndr (2014) 0.85
Costs of health resource utilization among HIV-positive individuals in British Columbia, Canada: results from a population-level study. Pharmacoeconomics (2015) 0.83
Antiretroviral drug costs and prescription patterns in British Columbia, Canada: 1996-2011. Med Care (2014) 0.80
Bayesian evidence synthesis to estimate HIV prevalence in men who have sex with men in Poland at the end of 2009. Epidemiol Infect (2015) 0.78
Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation. Patient Relat Outcome Meas (2015) 0.77
Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus and related health care costs: a real-life study in a large cohort of patients. Clinicoecon Outcomes Res (2014) 0.75
A population-based study of care at the end of life among people with HIV in Ontario from 2010 to 2013. J Acquir Immune Defic Syndr (2016) 0.75
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health (2007) 3.93
Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health (2011) 3.88
Safer injection facility use and syringe sharing in injection drug users. Lancet (2005) 3.85
Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis (2008) 3.38
Systematic review: Effects, design choices, and context of pay-for-performance in health care. BMC Health Serv Res (2010) 2.70
Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis (2005) 2.58
Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis (2011) 2.55
Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend (2006) 2.53
Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. CMAJ (2009) 2.51
Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res (2011) 2.45
Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet (2002) 2.44
Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime? Lancet (2008) 2.31
Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis (2005) 2.26
Education in pharmacoeconomics: an international multidisciplinary view. Pharmacoeconomics (2004) 2.25
Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS (2013) 2.17
A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan. Intern Med (2007) 2.17
Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. Am J Public Health (2010) 2.00
Quality of life after intensive care: a systematic review of the literature. Crit Care Med (2010) 1.96
Income generating activities of people who inject drugs. Drug Alcohol Depend (2007) 1.95
Effects of police confiscation of illicit drugs and syringes among injection drug users in Vancouver. Int J Drug Policy (2007) 1.90
Police and public health partnerships: evidence from the evaluation of Vancouver's supervised injection facility. Subst Abuse Treat Prev Policy (2008) 1.83
Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2012) 1.80
Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics (2005) 1.71
The development of artificial neural networks to predict virological response to combination HIV therapy. Antivir Ther (2007) 1.71
Enhanced HIV testing, treatment, and support for HIV-infected substance users. JAMA (2010) 1.67
Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study. BMJ (2006) 1.64
Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy (2009) 1.63
Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver. Drug Alcohol Depend (2005) 1.62
Drug treatment courts in Canada: an evidence-based review. HIV AIDS Policy Law Rev (2007) 1.59
Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS (2006) 1.57
Elevated overdose mortality rates among First Nations individuals in a Canadian setting: a population-based analysis. Addiction (2010) 1.57
Incarceration experiences in a cohort of active injection drug users. Drug Alcohol Rev (2008) 1.57
Effect of drug law enforcement on drug market violence: a systematic review. Int J Drug Policy (2011) 1.52
Vienna Declaration: a call for evidence-based drug policies. Lancet (2010) 1.52
Fifteen million people on antiretroviral treatment by 2015: treatment as prevention. Curr Opin HIV AIDS (2013) 1.51
The role of surrogate markers in the clinical development of antiretroviral therapy: a model for early evaluation of targeted cancer drugs. Cancer Invest (2004) 1.50
A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care (2002) 1.50
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
HIV risks associated with incarceration among injection drug users: implications for prison-based public health strategies. J Public Health (Oxf) (2008) 1.49
Health promotion in individuals with mental disorders: a cluster preference randomized controlled trial. BMC Public Health (2013) 1.44
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS (2003) 1.43
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer (2013) 1.43
Thinking ahead--the rising tide of AIDS orphans. S Afr Med J (2005) 1.41
Economic evaluations in healthcare: comments on a recent article. Reprod Biomed Online (2005) 1.40
The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study. AIDS Care (2009) 1.38
A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population. Nephron Clin Pract (2008) 1.36
Homelessness as a structural barrier to effective antiretroviral therapy among HIV-seropositive illicit drug users in a Canadian setting. AIDS Patient Care STDS (2011) 1.33
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy. Artif Intell Med (2009) 1.31
Estimated drug overdose deaths averted by North America's first medically-supervised safer injection facility. PLoS One (2008) 1.31
Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. Antivir Ther (2004) 1.30
The urgency of providing comprehensive and integrated treatment for substance abusers with HIV. Health Aff (Millwood) (2011) 1.29
Homelessness independently predicts injection drug use initiation among street-involved youth in a Canadian setting. J Adolesc Health (2012) 1.27
Cohort profile: the Canadian Observational Cohort collaboration. Int J Epidemiol (2010) 1.27
Changes in injecting practices associated with the use of a medically supervised safer injection facility. J Public Health (Oxf) (2007) 1.26
Modelling crack cocaine use trends over 10 years in a Canadian setting. Drug Alcohol Rev (2010) 1.24
Canada's 2003 renewed drug strategy--an evidence-based review. HIV AIDS Policy Law Rev (2006) 1.22
Barriers to HIV treatment among people who use injection drugs: implications for 'treatment as prevention'. Curr Opin HIV AIDS (2012) 1.22
Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare. BMC Infect Dis (2011) 1.20
Nonfatal overdose among a cohort of street-involved youth. J Adolesc Health (2007) 1.18
Interest in low-threshold employment among people who inject illicit drugs: implications for street disorder. Int J Drug Policy (2011) 1.18
Social and structural factors associated with HIV disease progression among illicit drug users: a systematic review. AIDS (2012) 1.18
Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study. Int J Epidemiol (2009) 1.17
Migration adversely affects antiretroviral adherence in a population-based cohort of HIV/AIDS patients. Soc Sci Med (2009) 1.15
Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico. J Acquir Immune Defic Syndr (2010) 1.14
Risks surrounding drug trade involvement among street-involved youth. Am J Drug Alcohol Abuse (2008) 1.14
Housing status and the health of people living with HIV/AIDS. Curr HIV/AIDS Rep (2012) 1.13
Canada's new federal 'National Anti-Drug Strategy': an informal audit of reported funding allocation. Int J Drug Policy (2008) 1.13
Injection drug use cessation and use of North America's first medically supervised safer injecting facility. Drug Alcohol Depend (2010) 1.13
Changing epidemiology of HCV and HBV infections in Northern Italy: a survey in the general population. J Clin Gastroenterol (2008) 1.11
Daily cost of antimicrobial therapy in patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection. Int J Antimicrob Agents (2008) 1.11
Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting. Antivir Ther (2010) 1.10
Cost effectiveness of treatments for wet age-related macular degeneration. Pharmacoeconomics (2011) 1.09
Treatment as prevention: preparing the way. J Int AIDS Soc (2011) 1.09
What reimbursement for coronary revascularization with drug-eluting stents? Eur J Health Econ (2004) 1.09
The ties that bind: an integrative framework of physician-hospital alignment. BMC Health Serv Res (2011) 1.08
Crystal methamphetamine use associated with non-fatal overdose among a cohort of injection drug users in Vancouver. Public Health (2007) 1.08
Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: a systematic review. Int J Behav Nutr Phys Act (2011) 1.08
Incarceration and drug use patterns among a cohort of injection drug users. Addiction (2009) 1.07
A description of a peer-run supervised injection site for injection drug users. J Urban Health (2005) 1.06
Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis (2006) 1.05
Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. Mov Disord (2008) 1.03
Seek and treat to optimize HIV and AIDS prevention. CMAJ (2012) 1.02
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin Infect Dis (2007) 1.02
The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction (2014) 1.02
Health related quality of life in coronary patients and its association with their cardiovascular risk profile: results from the EUROASPIRE III survey. Int J Cardiol (2012) 1.02
Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol (2012) 1.01
Public crack cocaine smoking and willingness to use a supervised inhalation facility: implications for street disorder. Subst Abuse Treat Prev Policy (2011) 1.01
Crystal methamphetamine use among female street-based sex workers: Moving beyond individual-focused interventions. Drug Alcohol Depend (2011) 1.01
Economic evaluation of HIV treatments: the I.CO.N.A. cohort study. Health Policy (2005) 1.00
Crystal methamphetamine and initiation of injection drug use among street-involved youth in a Canadian setting. CMAJ (2013) 0.99
Violence among street-involved youth: the role of methamphetamine. Eur Addict Res (2008) 0.99
Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine (2008) 0.98
Addiction treatment-related employment barriers: the impact of methadone maintenance. J Subst Abuse Treat (2012) 0.98
Psychological well-being and socio-economic hardship among AIDS orphans and other vulnerable children in Guinea. AIDS Care (2009) 0.97
HIV risks in incarcerated injection-drug users. Lancet (2005) 0.97
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr (2008) 0.97